Advertisement

A prospective study of 17 autoantibodies (AA) in 176 cases of rheumatoid arthritis (RA) treated with D-penicillamine (DP) (Abstract)

  • P. Youinou
  • J.-F. Morin
  • M. Raulo
  • N. Abuaf
  • J.-C. Homberg
Part of the Inflammation: Mechanisms and Treatment book series (FTIN, volume 4)

Abstract

176 patients (36 male/140 female; mean age, 54, range 20–87) suffering from classical or definite RA as defined by the ARA criteria were given a slowly increasing dosage of DP. The overall mean durationof DP was 22 months (6–36); the mean dose level was 16 mg/kg daily (10–25) and the mean RA duration was 92 months (11–431). 17 AA were determined before, during and after the treatment. Within 2 months of giving DP, the rheumatoid factors titre decreased, whereas antiperinuclear factor remained unchanged throughout the treatment. Between the 6th and the 12th month, various AA appeared in 12% of the patients (to ds-DNA, to skeletal muscle and to epidermal intercellular substance). Associated autoimmune disease was noted in 50% of the latter. The patients with a positive anti-nuclear factor seemed especially likely to develop a serious side effect.

Keywords

Public Health Rheumatoid Arthritis Skeletal Muscle Autoimmune Disease Dose Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© MTP Press Limited 1980

Authors and Affiliations

  • P. Youinou
    • 1
  • J.-F. Morin
    • 1
  • M. Raulo
    • 1
  • N. Abuaf
    • 1
  • J.-C. Homberg
    • 1
  1. 1.France

Personalised recommendations